Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
34 - Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
from Section 4 - Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
The Global Alzheimer’s Association Interactive Network (GAAIN) connects researchers to data collected by Alzheimer’s disease (AD) and dementia studies from around the world. To date, GAAIN links together 54 data partners, over 500,000 subjects, and over 30,000 data attributes into one navigable network. Studies that participate in GAAIN benefit from increased publicity, exposure, and opportunities for collaboration while keeping data ownership and subject privacy protected. Researchers who use GAAIN can discover new data sets, visualize results of preliminary analyses, and are directed on how to apply for data access. The architecture underlying GAAIN is uniquely designed to address the different needs of both data partners and researchers. GAAIN supports both longitudinal and cross-sectional studies, and it is fully leveraged when researchers aggregate multiple studies across different countries and continents into meta-analyses. Exploration of remote data and analyses can ultimately benefit clinical trials as well as contribute to the global effort to solve AD and dementia-related pathologies.
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 395 - 403Publisher: Cambridge University PressPrint publication year: 2022
References
Conrado, DJ, Karlsson, MO, Romero, K, et al. Open innovation: towards sharing of data, models and workflows. Eur J Pharm Sci 2017; 109: S65–71.CrossRefGoogle Scholar
Gurevitch, J, Koricheva, J, Nakagawa, S, et al. Meta-analysis and the science of research synthesis. Nature 2018; 555: 175–82.CrossRefGoogle ScholarPubMed
Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16: 391–460.Google Scholar
Villa, C, Lavitrano, M, Salvatore, E, et al. Molecular and imaging biomarkers in Alzheimer’s disease: a focus on recent insights. J Pers Med 2020; 10: 1–32.Google Scholar
Sancesario, GM, Bernardini, S. Alzheimer’s disease in the omics era. Clin Biochem 2018; 59: 9–16.Google Scholar
Toga, AW, Neu, SC, Bhatt, P, et al. The Global Alzheimer’s Association Interactive Network. Alzheimers Dement 2016; 12: 49–54.Google Scholar
Neu, SC, Crawford, KL, Toga, AW. Sharing data in the global Alzheimer’s Association Interactive Network. Neuroimage 2016; 124: 1168–74.CrossRefGoogle ScholarPubMed
Kraus, WE, Bhapkar, M, Huffman, KM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, Phase 2, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7: 673–83.Google Scholar
Silva, MVF, Loures, CDMG, Alves, LCV, et al. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci 2019; 26: 1–11.CrossRefGoogle ScholarPubMed
Rygiel, K. Novel strategies for Alzheimer’s disease treatment: an overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 2016; 48: 629–36.CrossRefGoogle ScholarPubMed
Tariot, PN, Lopera, F, Langbaum, JB, et al. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4: 150–60.Google Scholar
Mills, SM, Mallmann, J, Santacruz, AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 2013; 169: 737–43.Google Scholar
Sperling, RA, Donohue, MC, Raman, R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol 2020; 77: 735–45.CrossRefGoogle ScholarPubMed
Tang, MX, Stern, Y, Marder, K, et al. The APOE-ε4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998; 279: 751–5.CrossRefGoogle ScholarPubMed
Duara, R, Loewenstein, DA, Lizarraga, G, et al. Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. Neuroimage Clin 2019; 22: 101800.Google Scholar
O’Bryant, SE, Zhang, F, Johnson, LA, et al. A precision medicine model for targeted NSAID therapy in Alzheimer’s disease. J Alzheimers Dis 2018; 66: 97–104.CrossRefGoogle ScholarPubMed
Li, Y, Li, Y, Li, X, et al. Head injury as a risk factor for dementia and Alzheimer’s disease: a systematic review and meta-analysis of 32 observational studies. PLoS One 2017; 12: e0169650.CrossRefGoogle ScholarPubMed
Neu, SC, Pa, J, Kukull, W, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 2017; 74: 1178–89.CrossRefGoogle ScholarPubMed
Funk-White, M, Moore, AA, McEvoy, LK, et al. Alcohol use patterns and cognitive impairment: a cross-country comparison. Alzheimer’s Association International Conference, July 26–30, 2020.Google Scholar
Rane, S. Detecting cortical signatures of suspected non-amyloid pathology using large harmonized datasets. Alzheimer’s Association International Conference, July 26–30, 2020.CrossRefGoogle Scholar
Crawford, KL, Neu, SC, Toga, AW. The Image and Data Archive at the Laboratory of Neuro Imaging. Neuroimage 2016; 124: 1080–3.CrossRefGoogle ScholarPubMed
Weiner, MW, Aisen, PS, Jack, CR, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202–11.CrossRefGoogle Scholar
Beekly, DL, Ramos, EM, van Belle, G, et al. The National Alzheimer’s Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 2004; 18: 270–7.Google Scholar
Anthony, S, Pradier, C, Chevrier, R, et al. The French national Alzheimer database: a fast growing database for researchers and clinicians. Dement Geriatr Cogn Disord 2014; 38: 271–80.Google Scholar
- 1
- Cited by